PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.95
Negative P/E while RVPH shows 49.80. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
6.36
P/B 1.1-1.25x RVPH's 5.45. Bill Ackman would demand evidence of superior asset utilization.
-7.16
Negative FCF while RVPH shows P/FCF of 199.21. Joel Greenblatt would examine cash flow improvement potential.
-7.16
Negative operating cash flow while RVPH shows P/OCF of 199.21. Joel Greenblatt would examine operational improvement potential.
6.36
Fair value ratio 1.1-1.25x RVPH's 5.45. Bill Ackman would demand evidence of superior economics.
-12.82%
Negative earnings while RVPH shows yield of 0.50%. Joel Greenblatt would examine path to profitability.
-13.97%
Negative FCF while RVPH shows yield of 0.50%. Joel Greenblatt would examine cash flow improvement potential.